Communiqués Agenus Inc.

Actions

AGEN

US00847G8042

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
16,6 ^USD	+0,24 %		+5,80 %	+0,25 %

16/05	Agenus Inc. annonce que la FDA lui accorde une réunion de fin de phase 2 de type B pour discuter de la thérapie Bot/Bal pour le traitement du cancer colorectal métastatique récidivant ou réfractaire.	CI
07/05	Mise à jour sectorielle : Les actions du secteur de la santé sont plus fortes dans l'après-midi de mardi	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Agenus Announces Virtual Annual Shareholders Meeting	04/06	BU
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	24/05	BU
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting	23/05	BU
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference	23/05	BU
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer	16/05	BU
Agenus: Q1 Earnings Snapshot	07/05	AQ
Agenus Reports First Quarter 2024 Results	07/05	BU
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement	01/05	BU
Agenus Inc. - Botensilimab, Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting	25/04	AQ
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting	24/04	BU
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update	23/04	BU
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer	15/04	AQ
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer	12/04	BU
Agenus Announces Reverse Stock Split of Common Stock	05/04	BU
Agenus : Submission of Matters to a Vote of Security Holders - Form 8-K	05/04	PU
Agenus: Q4 Earnings Snapshot	14/03	AQ
Agenus Reports Fourth Quarter and Full Year 2023 Results	14/03	BU
Agenus Announces Preclinical Data on BMS-986442 at AACR 2024	07/03	AQ
Agenus Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	06/03	AQ
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024	06/03	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Agenus Inc.

Actions

AGEN

US00847G8042

Communiqués

Filtres